Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Homology Medicines

Homology Medicines
2015 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
FIXX STOCK SYMBOL
$16.48 SHARE PRICE (As of Thursday Closing)
Description

Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 45 Wiggins Avenue
  • Bedford, MA 01730
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Homology Medicines’s full profile, request a free trial.

Homology Medicines Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$11.05 - $31.80 $725M $16.17 -$2.50 354K 44M

Homology Medicines Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 499,992 600,861
Revenue 1,103 3,684 0 0
EBITDA (101,032) (60,275) (29,849) (7,831)
Net Income (100,173) (57,215) (29,991) (8,047)
Total Assets 316,759 259,094 137,530 14,219
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Homology Medicines Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.

Request full access to PitchBook

Homology Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Homology Medicines Competitors (68)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OncoResponse Venture Capital-Backed Seattle, WA 000.00 00000000000 000.00
0000 00000000000 Formerly VC-backed Redwood City, CA 00 00000 000000&0 00000
0000 000000 Formerly VC-backed San Diego, CA 00 00000 000000 - 000 00000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
0000000 0000000000 Formerly VC-backed Richmond, CA 000 000.00 00000000 000.00
To view this company’s complete list of competitors, request access »

Homology Medicines Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Homology Medicines‘s full profile, request access.

Request full access to PitchBook

Homology Medicines Executive Team (11)

Name Title Board
Seat
Contact
Info
Arthur Tzianabos Ph.D President, Board Member & Chief Executive Officer
Bradford Smith Chief Financial Officer
Albert Seymour Ph.D Chief Scientific Officer
CJ Witalisz Executive
Saswati Chatterjee Ph.D Co-Founder and Chair of the Scientific Advisory Board

2 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Homology Medicines Board Members (13)

Name Representing Role Since Contact
Info
Alise Reicin Homology Medicines Board Member 000 0000
Arthur Tzianabos Ph.D Homology Medicines President, Board Member & Chief Executive Officer 000 0000
Cameron Wheeler Ph.D Self Board Member 000 0000
Jason Ruth Ph.D 5AM Ventures Board Observer 000 0000
Kush Parmar Ph.D 5AM Ventures Chairman & Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »